Kalkine has a fully transformed New Avatar.

small-cap

One Health Care Equipment & Services Stock Trading Near Resistance Levels - CGS

Apr 05, 2024 | Team Kalkine
One Health Care Equipment & Services Stock Trading Near Resistance Levels - CGS

CGS:ASX
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (AU$)

This report is an updated version of the report published on the 5 April 2024 at 3:55 PM AEDT.

Cogstate Limited (ASX: CGS)

Cogstate Limited (ASX: CGS) is a neuroscience technology company based in the United States. The ASX-listed company is committed to optimising cognitive assessments to aid the development of new therapeutics and delivering earlier brain health insights in clinical care.

Recommendation Rationale – SELL at AUD 1.35

  • Financial Performance: Total revenue for the first half of FY24 stood at USD 20.2mn, up 3.6% YoY. CGS registered a net profit of USD 2mn in 1HFY24, up from USD 0.1mn in the year-ago period. The performance was driven by over 3% YoY revenue growth in clinical trials and cost reductions.
  • Outlook: CGS expects to register improvement in clinical trials sales bookings in the second half of FY24. Backed by the growing network of eCOA and CRO channel partners, the company anticipates further sales opportunities.
  • Emerging Risks: Failure to continually evolve its offering with new technology, systems and data analytics may impact the company’s market position.
  • Overvalued Multiples: On a forward 12-month basis, key valuation multiples (EV/EBITDA and Price/Earnings) are higher than the median of Healthcare.

CGS Daily Chart

Considering that the stock has surpassed its R1 level, the current trading levels, share price movement, and risks associated, it is prudent to book profit at the current levels. Hence, a ‘Sell’ recommendation is given on the stock at the current market price of AUD 1.35, at 10:15 AM as of April 05, 2024, AEST.

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and geopolitical issues prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is neither an indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is April 05, 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.

Stop-loss: In general, it is a level to protect further losses in case of any unfavourable movement in the stock prices.


Disclaimer-

This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services. Please note past performance is neither an indicator nor a guarantee of future performance.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.